Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3363

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3363
---
 and medical centers into products
that we believe have the potential to dramatically improve patients’ lives. Unlike many biotech companies, our success is not dependent
on any one particular program or disease. Our current pipeline is already well-diversified and our access to innovations from academic
and medical institutions allows us the flexibility to opportunistically develop product candidates, regardless of therapeutic area. We
believe our sources of medical discoveries include not only research universities and medical centers but also companies with assets
that are not core to their business model.

We
use highly selective criteria and stringent due diligence for selecting assets for development. Picking the right assets requires unbiased
and objective science/technology and market assessments that are not affected by institutional legacies, not blinded by research myopia
or academic necessities, and not influenced by “herd mentalities.” We seek to develop technologies that meet our stringent
selection criteria and which are amenable to our controlled de-risking process that we believe can lead to clear and timely value inflection
points and milestones. We intend to keep our focus on projects and technologies that demonstrate clear progress towards becoming commercially
viable products. Our business model aims to diversify our approach away from a single vector of technology research or science, and instead
to pursue a variety of promising research avenues simultaneously and cost effectively. As explained previously, we believe that we can
address the resourcing challenges inherent in such diversity and that the diversity itself is an advantageous business strategy.

Our
model for identifying, structuring and developing assets is based on the following tenets:

    ●
    We
    believe we have a disciplined process for identification, selection and prioritization of programs: We believe that only well-defined
    science can be monetized successfully. Independent analyses of pharmaceutical research and development productivity indicate that
    ill-defined science is a major cause of low success rates and eventual failure of programs. We believe that there is no substitute
    for a thorough science/technology assessment upfront as it is essential to have a clear understanding of the science and a clear
    vision of how a technology becomes a product before starting the development effort.

    ●
    Our
    approach to selecting programs is opportunistic: We seek opportunities based on solid science, well-characterized drug mechanisms
    of action, and targets with true disease-modifying potential that can address significant unmet medical needs. While many such opportunities
    may be found at leading universities and medical centers, we search for promising technologies wherever they can be found. We believe